home

Breaking News

Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.

see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB (initial proof of safety and efficacy) and Phase II Clinical Trials have been successfully completed.


©2009 Redox Pharmaceutical Corporation.
All rights reserved.

Send us your site suggestions & service requests.

Site hosted by: Transbeam.com

OUR COMPANY

Redox Pharmaceutical Corporation has patented a family of metallo-organic compounds with demonstrated effectiveness in antiviral, antibacterial and anti-inflammatory applications...

 

MEDICAL APPLICATIONS

OCULAR APPLICATIONS
   Adenovirus-derived
   Keratoconjunctivitis

   Herpetic Keratitis

DERMAL APPLICATION
   Facial Herpes

ANTI-INFLAMMATORY APPLICATION
   Non-Steroidal anti-inflammatory

GENITAL APPLICATIONS
   Overview
   HIV
   Human Papillomavirus
   Genital Herpes
  

 

Contact Us | Home